Lief's $1.3 million sale of Arena shares was disclosed in an SEC filing last week.
The hip waders I normally wear for protection from biotech bullshit aren't tall enough to wade through Ampio's current press release. I need a full haz-mat suit.
Investors aren't yet recognizing Vertex's ability to develop triple-combo therapies for hardest-to-treat cystic fibrosis patients.
A phase II study of Squalamine in wet age-related macular degeneration bombed badly.
Based on positive study results, Vertex will seek approval for the cystic fibrosis regimen of VX-809 and Kalydeco in the fourth quarter.
MD Anderson released a statement criticizing Northwest Bio on Friday night after company shareholders and supporters flamed the hospital's Facebook page with hateful comments.
Conspicuously absent from Northwest Biotherapeutics' press release Friday was any mention of the MD Anderson Cancer Center.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Northwest Bio has issued five press releases and held a conference call in the past month to disclose preliminary and unconfirmed results from individual cancer patients who have had single, inoperable tumors injected repeatedly with DCVax-Direct. But investigators at MD Anderson and the two other hospitals conducting the DCVax-Direct study have not reviewed or analyzed data at all because patients are still being enrolled and treated.
Let's wind back the tape more than 9 years to documents the many instances in which MannKind executives made promises about partnering the inhaled insulin Afrezza.